Nephron Research analyst Thomas DeBourcy downgraded Zoetis (ZTS) to Hold from Buy with a $131 price target The firm cites a lack of organic growth for the downgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis to acquire Neogen animal genomics business for $160M
- Zoetis: VMD Review Reinforces Librela Safety Profile and Supports Buy-Rated Growth Outlook
- Zoetis Earnings Call: Growth Holds Amid Competitive Strain
- Zoetis’ Convertible Notes Trigger Liquidity and Reporting Risks if Conditional Conversion Kicks In
- Zoetis price target raised to $140 from $135 at BofA